Discover trends, market shifts, and competitive outlooks for the viral hepatitis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Viral Hepatitis Market Size from 2025 to 2034?

The market size for viral hepatitis has consistently been on the rise over the past few years. Its growth is forecasted to ascend from $16.21 billion in 2024 to $16.93 billion in 2025, marking a compound annual growth rate (CAGR) of 4.4%. Factors such as the development of vaccines, blood screening programs, antiviral medications, and worldwide health initiatives have been instrumental in facilitating growth in the historical period.

In the coming years, the market size for viral hepatitis is envisioned to experience consistent growth. The predicted compound annual growth rate (CAGR) is 4.2%, thus making the market worth $19.97 billion by the year 2029. The projected growth during this period can be linked to factors like availability of treatment, public health legal provisions, combination therapeutic strategies, and initiatives for health equity. Notable tendencies during the forecast era include customised treatment blueprints, digital healthcare instruments, application of artificial intelligence in disease tracking, and micro-elimination of hepatitis C.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Viral Hepatitis Market?

The escalating incidences of hepatitis are predicted to stimulate the expansion of the viral hepatitis market. Hepatitis, a liver infection, can be instigated by numerous infectious viruses and non-infectious materials, leading to a host of health conditions. Viral hepatitis is induced by Hepatitis A, B, C, D, and E and it brings about inflammation and harm to the liver. For example, the European Centre for Disease Prevention and Control reported in April 2024, that hepatitis B virus (HBV) infection cases had escalated to 28,855 across 30 EU/EEA Member States in 2022, an escalation of 78% compared to the 16,187 cases recorded in 2021. Furthermore, a case count amounting to 28,420 in 2022, represented a crude rate of 8.5 instances per 100,000 persons. Thus, the escalating prevalence of hepatitis is a substantial driver of the viral hepatitis market. The rising trajectory of the viral hepatitis market can be tied to the surge in research and development activities. Research and development (R&D) for viral hepatitis involves various avenues such as the development of vaccines, antiviral medications, diagnostic tests, epidemiological investigations, public health strategies, genomic research, prevention tactics, global health initiatives, clinical trials, and research into co-infections. The surge in such activities leads to treatment innovation, greater diagnostic and prevention choice, a higher quantity of clinical trials, improved global health initiatives, and stiffer competition amongst pharmaceutical firms. For instance, The Peter Doherty Institute for Infection and Immunity, based in Australia, reported in November 2022 that Melbourne researchers have successfully procured $1.7 million in funding for the next five years through the mRNA Victoria Activation Program to further their groundbreaking work on finding a cure for hepatitis B virus infection. Therefore, the surge in research and development activities is a significant factor propelling the viral hepatitis market expansion.

What Segment Types Define the Viral Hepatitis Market Structure?

The viral hepatitis market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis

3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A

2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier

3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C

4) By Other Disease Types: Hepatitis D, Hepatitis E

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Viral Hepatitis Market?

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Viral Hepatitis Market?

Firms in the viral hepatitis marketplace are progressing new medications and improvements to maintain their industry standing. Drug discovery and innovation enhance scientific comprehension by shedding light on disease mechanisms and speeding up the creation of new remedies. For example, in November 2022, Gilead Sciences Inc., a biopharmaceutical entity based in the US, reported that the Food and Drug Administration (FDA) had authorized the additional new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This is intended as a daily treatment for chronic hepatitis B virus (HBV) infection in children who are 12 years or older with compensated liver disease. The approval of Vemlidy for this pediatric patient group was backed by the results of a 24-week Phase 2 clinical trial.

View the full report here:

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

What Is the Definition of the Viral Hepatitis Market?

Viral hepatitis refers to a group of infectious diseases caused by different viruses (hepatitis A, B, C, D and E), which primarily affect the liver. The symptoms can vary depending on the specific virus, but common manifestations include fatigue, jaundice, abdominal pain, nausea, vomiting and fever.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model